Ghent University Academic Bibliography

Advanced

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

Leen De Rycke, Xavier Verhelst UGent, Elli Kruithof, Filip Van Den Bosch, Ilse Hoffman, Eric Veys UGent and Filip De Keyser UGent (2005) ANNALS OF THE RHEUMATIC DISEASES. 64(2). p.299-302
abstract
Objectives: To analyse the effect of infliximab on IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies, and determine whether baseline autoantibody titres (IgM RF and anti-CCP antibodies) are associated with changes in acute phase reactants. Patients and methods: 62 patients with refractory RA were treated with infliximab combined with methotrexate. At baseline and week 30, serum samples were tested for IgM RF by two agglutination assays, and for anti-CCP antibodies by an ELISA. Percentage change in C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) was calculated. Results: At baseline and week 30 RF titres were reduced significantly during infliximab treatment (p < 0.001 and p = 0.038, respectively), whereas anti-CCP antibodies were unchanged (p = 0.240). Baseline IgM RF titres, but not anti-CCP antibodies, correlated inversely with changes in CRP and ESR during treatment. Patients with a marked decrease in acute phase reactants had lower IgM RF titres than those with a smaller decrease in CRP and ESR; no significant differences were found for anti-CCP antibodies. Conclusion: The differential effect of infliximab treatment on IgM RF and anti-CCP antibodies, and the different predictive value on changes in acute phase reactants during infliximab treatment support the existing evidence that RF and anti-CCP antibodies are independent autoantibody systems in RA.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
METHOTREXATE, IGM, ASSOCIATION, THERAPY, ALPHA
journal title
ANNALS OF THE RHEUMATIC DISEASES
Ann. Rheum. Dis.
volume
64
issue
2
pages
299 - 302
Web of Science type
Article
Web of Science id
000226279200027
JCR category
RHEUMATOLOGY
JCR impact factor
6.956 (2005)
JCR rank
2/22 (2005)
JCR quartile
1 (2005)
ISSN
0003-4967
DOI
10.1136/ard.2004.023523
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
329629
handle
http://hdl.handle.net/1854/LU-329629
date created
2006-04-10 10:00:00
date last changed
2012-10-30 10:41:36
@article{329629,
  abstract     = {Objectives: To analyse the effect of infliximab on IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies, and determine whether baseline autoantibody titres (IgM RF and anti-CCP antibodies) are associated with changes in acute phase reactants. 
Patients and methods: 62 patients with refractory RA were treated with infliximab combined with methotrexate. At baseline and week 30, serum samples were tested for IgM RF by two agglutination assays, and for anti-CCP antibodies by an ELISA. Percentage change in C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) was calculated. 
Results: At baseline and week 30 RF titres were reduced significantly during infliximab treatment (p {\textlangle} 0.001 and p = 0.038, respectively), whereas anti-CCP antibodies were unchanged (p = 0.240). Baseline IgM RF titres, but not anti-CCP antibodies, correlated inversely with changes in CRP and ESR during treatment. Patients with a marked decrease in acute phase reactants had lower IgM RF titres than those with a smaller decrease in CRP and ESR; no significant differences were found for anti-CCP antibodies. 
Conclusion: The differential effect of infliximab treatment on IgM RF and anti-CCP antibodies, and the different predictive value on changes in acute phase reactants during infliximab treatment support the existing evidence that RF and anti-CCP antibodies are independent autoantibody systems in RA.},
  author       = {De Rycke, Leen and Verhelst, Xavier and Kruithof, Elli and Van Den Bosch, Filip and Hoffman, Ilse and Veys, Eric and De Keyser, Filip},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keyword      = {METHOTREXATE,IGM,ASSOCIATION,THERAPY,ALPHA},
  language     = {eng},
  number       = {2},
  pages        = {299--302},
  title        = {Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis},
  url          = {http://dx.doi.org/10.1136/ard.2004.023523},
  volume       = {64},
  year         = {2005},
}

Chicago
De Rycke, Leen, Xavier Verhelst, Elli Kruithof, Filip Van Den Bosch, Ilse Hoffman, Eric Veys, and Filip De Keyser. 2005. “Rheumatoid Factor, but Not Anti-cyclic Citrullinated Peptide Antibodies, Is Modulated by Infliximab Treatment in Rheumatoid Arthritis.” Annals of the Rheumatic Diseases 64 (2): 299–302.
APA
De Rycke, Leen, Verhelst, X., Kruithof, E., Van Den Bosch, F., Hoffman, I., Veys, E., & De Keyser, F. (2005). Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES, 64(2), 299–302.
Vancouver
1.
De Rycke L, Verhelst X, Kruithof E, Van Den Bosch F, Hoffman I, Veys E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. ANNALS OF THE RHEUMATIC DISEASES. 2005;64(2):299–302.
MLA
De Rycke, Leen, Xavier Verhelst, Elli Kruithof, et al. “Rheumatoid Factor, but Not Anti-cyclic Citrullinated Peptide Antibodies, Is Modulated by Infliximab Treatment in Rheumatoid Arthritis.” ANNALS OF THE RHEUMATIC DISEASES 64.2 (2005): 299–302. Print.